...
首页> 外文期刊>American Journal of Nephrology >Potassium-binding resins: Associations with serum chemistries and interdialytic weight gain in hemodialysis patients
【24h】

Potassium-binding resins: Associations with serum chemistries and interdialytic weight gain in hemodialysis patients

机译:钾结合树脂:与血液透析患者血清化学物质和透析间增重的关系

获取原文
获取原文并翻译 | 示例
           

摘要

Background: Although potassium-binding sodium-based resins (K resins) have been prescribed to treat hyperkalemia for 50 years, there have been no large studies of their effects among hemodialysis (HD) patients. Methods: Data from 11,409 patients in the Dialysis Outcomes and Practice Patterns Study in Belgium, Canada, France, Italy, and Sweden (nations where ≥5% of patients were prescribed a sodium-based K resin; seven other countries had <5% use) between 2002 and 2011 were analyzed. Linear mixed models examined associations between K resin use and interdialytic weight gain (IDWG) and serum electrolyte concentrations. Mortality was analyzed using Cox regression. An instrumental variable approach was used to partially account for unmeasured confounders. Results: The K resin prescription rate was 20% overall. As hypothesized, patients prescribed a K resin had greater IDWG and higher serum bicarbonate, phosphorus, and sodium (but not calcium) concentrations. Patients prescribed a K resin had higher serum K levels, but serum K levels were lower in an instrumental variable analysis limiting treatment by indication bias. K resin use was not associated with mortality risk. Conclusion: We report the first large study of K resin use and associated laboratory and clinical outcomes in HD patients. The prescription rate of K resins varied dramatically by country and dialysis center. The results suggest that K resin use may effectively lower serum K, although at the expense of somewhat higher phosphatemia and greater IDWG, and had no clear association with mortality. Further study is warranted to elucidate the optimal role for K resins in modern dialysis care.
机译:背景:尽管已经开出了钾盐结合钠基树脂(K树脂)治疗高钾血症已有50年的历史,但对血液透析(HD)患者的疗效尚无大量研究。方法:来自比利时,加拿大,法国,意大利和瑞典的透析结果和实践模式研究中的11,409名患者的数据(这些国家中≥5%的患者处方了钠基K树脂;其他七个国家的使用率<5% )进行了分析。线性混合模型检查了钾树脂用量与透析间增重(IDWG)和血清电解质浓度之间的关联。使用Cox回归分析死亡率。使用工具变量方法来部分解决无法衡量的混杂因素。结果:钾树脂的处方总率为20%。如假设的那样,患者开出的K树脂的IDWG值较高,血清碳酸氢盐,磷和钠(而非钙)的浓度较高。开具K树脂的患者血清K水平较高,但在仪器变量分析中,血清K水平较低,这是由于适应症导致的。钾树脂的使用与死亡风险无关。结论:我们报道了首例针对HD患者使用钾树脂及其相关实验室和临床结果的大型研究。 K树脂的处方率因国家和透析中心而异。结果表明,使用K树脂可有效降低血清K,尽管会以略高的磷酸盐血症和更大的IDWG为代价,并且与死亡率无明显关联。有必要进行进一步的研究来阐明K树脂在现代透析护理中的最佳作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号